文献速递艾滋病与性传播感染

治疗性免疫恢复与CXCR4嗜性HIV-1的减少

Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
PubMed 文献 · Clin Infect Dis · 2016-11-12

本研究对35例接受完全抑制性cART的瑞士HIV队列患者进行纵向随访,用下一代测序检测X4嗜性前病毒的相对频率。80%患者治疗期间X4嗜性前病毒频率未增加,其余20%的X4扩增源于治疗前已存在的少数变异。结果表明成功治疗下X4嗜性HIV急剧下降,提示免疫 competent宿主中嗜性依赖的前病毒优先清除。

要点

  • 成功cART治疗下多数患者X4嗜性前病毒频率不增加,X4嗜性HIV急剧下降。
  • 少数患者X4扩增源于治疗前已存在的少数变异,非新发突变。
  • WHO立即启动治疗策略与治疗中X4嗜性逐渐丧失一致,或支持早期使用核心受体拮抗剂。

核心结论

  • 成功治疗期间多数患者X4嗜性HIV急剧下降,提示免疫 competent宿主中嗜性依赖的前病毒优先消除。

研究设计与样本

  • 对35例瑞士HIV队列研究中接受完全抑制性cART且CD4持续恢复的患者进行纵向随访。
  • 采用下一代测序检测前病毒X4嗜性变异相对频率,假阳性率3.5%,R5或X4变异低于总病毒群2%视为阈值。

主要发现

  • 80%患者在治疗期间X4嗜性前病毒频率无增加。
  • 超过50%患者可证明前病毒序列进化,但病毒多样性增长未伴随X4嗜性前病毒变异的出现或扩增。
  • 其余20%患者X4嗜性前病毒扩增基于治疗开始前已存在的少数变异群中单一变异的选择性生长。

临床怎么用

  • 支持WHO立即启动治疗策略,因治疗中X4嗜性逐渐丧失。
  • 或可考虑早期使用核心受体拮抗剂针对残留CCR5嗜性病毒。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the absence of therapy, CXCR4 (X4)-tropic human immunodeficiency virus type 1 (HIV-1) increases over time, associated with accelerated disease progression. In contrast, the majority of patients receiving long-term combination antiretroviral therapy (cART) present with CCR5 (R5)-tropic HIV-1 variants. It is unclear whether cART itself mediates the reduction of X4-tropic HIV-1. The current study aimed at assessing the tropism of viral integrates in patients' blood during fully suppressive cART. METHODS: The relative frequencies of X4-tropic proviral HIV-1 variants were determined by means of next-generation sequencing (False Positive Rate (FPR), 3.5%; R5- or X4 tropic variants occurring at less than 2% of the total virus population) for 35 treated patients in the Swiss HIV Cohort Study and followed longitudinally over time. Full viral suppression and a continuous CD4 T-cell recovery during cART were documented for all patients. Viral phylogenetic changes and sequence evolution were analyzed. RESULTS: The majority of patients (80%) experienced no frequency increase in X4-tropic proviruses during therapy. Although some proviral sequence evolution was demonstrable in >50% of these patients during therapy, this growing viral diversity was in no case paralleled by the emergence or expansion of X4-tropic provirus variants. In the remaining 20% of patients, the documented expansion of X4-tropic provirus was based on the outgrowth of single viral variants from minority populations already present before therapy initiation. CONCLUSION: Our study demonstrates that X4-tropic HIV sharply declines in most patients during successful therapy, which indicates a preferential tropism-dependent provirus elimination in the immunocompetent host. The recently implemented World Health Organization strategies of immediate therapy initiation are fully in line with this gradual loss of X4 tropism during therapy. Moreover, the early use of coreceptor antagonists against the remaining CCR5-tropic viruses may be indicated.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bader J, Däumer M, Schöni-Affolter F, et al. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. Clin Infect Dis. 2016. PMID: 27838645. doi:10.1093/cid/ciw737

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。